非实性肺结节随访与治疗决策分析
该研究基于Lung-RADS推荐,用决策分析模型模拟100万例磨玻璃结节患者,比较年度与3年间隔随访及不同治疗策略。模型提示随访间隔可从1年延长至3年而结局变化极小;立体定向体部放疗在非实性结节中结局优于肺叶切除和无治疗。
要点
- 持续存在的非实性结节恶性风险高于Lung-RADS 2类和3类估计值(3% vs 分别<1%和1%-2%)。
- Lung-RADS 4B或4X结节中仅30%(18 668/62 559)为临床显著恶性。
- 模型提示磨玻璃结节随访间隔可从1年延长至3年,结局变化极小。
核心结论
- 模拟模型提示磨玻璃结节随访间隔可从1年延长至3年而结局变化极小;对非实性结节,立体定向体部放疗结局优于肺叶切除和无治疗。
研究设计与样本
- 决策分析模拟研究,纳入1 000 000例假设的磨玻璃结节患者,按Lung-RADS推荐随访,初始年龄55-75岁(平均64岁),临床显著恶性率参照美国国家肺筛查试验数据校准。
诊断标准与关键数值
- 临床显著恶性占全部结节的2.3%(22 584/1 000 000),接受治疗者占6.3%(62 559/1 000 000)。
- Lung-RADS 4B或4X结节中临床显著恶性仅30%(18 668/62 559)。
- 基线后持续存在的非实性结节临床显著恶性风险3%,高于Lung-RADS 2类(<1%)和3类(1%-2%)的估计值。
- 10年总生存:年度随访72%(527 827/737 306;95%CI:71%,72%)vs 3年间隔随访71%(526 507/737 306;95%CI:71%,72%),P<.01。
- 进展至Lung-RADS 4B或4X者10年总生存:放疗80%(49 945/62 559;95%CI:80%,80%)vs 手术79%(49 139/62 559;95%CI:78%,79%)vs 无治疗74%(46 512/62 559;95%CI:74%,75%),P<.01。
临床应用与阅片要点
- 模型提示持续存在的非实性结节实际恶性风险可能高于Lung-RADS 2类和3类的估计值,阅片报告时可结合此点描述。
- 模型提示磨玻璃结节随访间隔可从1年延长至3年而结局变化极小。
- 对非实性结节,模型显示立体定向体部放疗10年总生存高于肺叶切除和无治疗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Purpose To evaluate management strategies and treatment options for patients with ground-glass nodules (GGNs) by using decision-analysis models. Materials and Methods A simulation was developed for 1 000 000 hypothetical patients with GGNs undergoing follow-up per the Lung Imaging Reporting and Data System (Lung-RADS) recommendations. The initial age range was 55-75 years (mean, 64 years). Nodules could grow and develop solid components over time. Clinically significant malignancy rates were calibrated to data from the National Lung Screening Trial. Annual versus 3-year-interval follow-up of Lung-RADS category 2 nodules was compared, and different treatment strategies were tested (stereotactic body radiation therapy, surgery, and no therapy). Results Overall, 2.3% (22 584 of 1 000 000) of nodules were clinically significant malignancies; 6.3% (62 559 of 1 000 000) of nodules were treated. Only 30% (18 668 of 62 559) of Lung-RADS category 4B or 4X nodules were clinically significant malignancies. The risk of clinically significant malignancy for persistent nonsolid nodules after baseline was higher than Lung-RADS estimates for categories 2 and 3 (3% vs <1% and 1%-2%, respectively). Overall survival (OS) at 10 years was 72% (527 827 of 737 306; 95% confidence interval [CI]: 71%, 72%) with annual follow-up and 71% (526 507 of 737 306; 95% CI: 71%, 72%) with 3-year-interval follow-up (P < .01). At 10 years, OS among patients whose nodules progressed to Lung-RADS category 4B or 4X was 80% after radiation therapy (49 945 of 62 559; 95% CI: 80%, 80%), 79% after surgery (49 139 of 62 559; 95% CI: 78%, 79%), and 74% after no therapy (46 512 of 62 559; 95% CI: 74%, 75%) (P < .01). Conclusion Simulation modeling suggests that the follow-up interval for evaluating ground-glass nodules can be increased from 1 year to 3 years with minimal change in outcomes. Stereotactic body radiation therapy demonstrated the best outcomes compared with lobectomy and with no therapy for nonsolid nodules. © RSNA, 2018 Online supplemental material is available for this article.
引用
- Hammer MM, Palazzo LL, Eckel AL, et al. A Decision Analysis of Follow-up and Treatment Algorithms for Nonsolid Pulmonary Nodules. Radiology. 2018. PMID: 30457486. doi:10.1148/radiol.2018180867
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。